Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 5, 2006 Brian Lawler	Cubist Finds an Asian Partner The smaller drug developer teams up with AstraZeneca to bring its antibiotic to worldwide markets. The best part of the deal is that Cubist retains the rights to Cubicin in Japan, which is by far the biggest market in all of Asia. Investors, take note.
The Motley Fool May 12, 2004 Charly Travers	Cubist Addresses a Niche Market This small firm is developing antibiotics to meet a medical need.
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
The Motley Fool April 6, 2011 Brian Orelli	Killing Bacteria With the Help of a Friend Optimer Pharmaceuticals has signed up Cubist Pharmaceuticals as a marketing partner for at least the next two years.
The Motley Fool October 20, 2006 Brian Lawler	Cubist Paints a Greener Picture The pharmaceutical company is flush with cash and finally profitable. However, it might just be easier for Cubist to sell itself to a more substantial pharmaceutical company. Investors, take note.
The Motley Fool July 20, 2006 Brian Lawler	Cubist's Square Results The pharmaceutical company has a promising new drug, but little else in the pipeline. Investors, take note.
The Motley Fool October 20, 2011 Travis Hoium	Cubist Pharmaceuticals Shares Popped: What You Need to Know Shares of Cubist Pharmaceuticals jumped 10% today after the company released earnings.
The Motley Fool January 26, 2005 Charly Travers	Call Cubist in the Morning Strong drug sales provide a dose of good medicine for this pharmaceutical.
The Motley Fool December 28, 2007 Brian Lawler	Cubist's Cheap Call Option As a Christmas Eve present to itself, Cubist Pharmaceuticals follows through on its October option to purchase Illumigen.
The Motley Fool October 27, 2004 Charly Travers	Cubist's Growing Pains The pharmaceutical is going to have to work through some growing pains and make strides toward profitability before the performance of the stock will match the performance of its drug.
The Motley Fool June 28, 2005 Charly Travers	Growth Around the Corner? Despite a thin pipeline, small biotech Cubist Pharmaceuticals is hoping to ride the wave of prosperity. Investors, take note.
The Motley Fool April 8, 2005 Brian Gorman	Cubist in Neutral Cubist Pharmaceuticals' pipeline may be why investors are unimpressed.
The Motley Fool January 29, 2007 Brian Lawler	No Dicey Results for Cubist The stock price may be down, but Cubist Pharmaceuticals is looking strong.
BusinessWeek October 29, 2007 Catherine Arnst	Superbugs: Where Are the Wonder Drugs? Antibiotics are losing the battle against superbugs, and drugmakers are slow to replenish the arsenal.
The Motley Fool April 5, 2011 Cindy Johnson	Cubist Pharmaceuticals Shares Popped: What You Need to Know Cubist Pharmaceuticals popped as much as 17% in intraday trading today after announcing a licensing agreement and the settlement of a patent dispute.
The Motley Fool December 31, 2009 Brian Orelli	The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims.
The Motley Fool April 5, 2011 Brian Orelli	Suit Settlement Sends Shares Skyrocketing Cubist Pharmaceuticals gets concessions as it settles its patent suit with Teva.
The Motley Fool March 25, 2009 Brian Orelli	Wyeth: Now Approved to Kill More Bugs! Wyeth's antibiotic gets approved for another indication.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool November 28, 2008 Brian Orelli	The FDA's Killing Bug Killers Unfortunately for Johnson & Johnson and Swiss drugmaker Basilea Pharmaceutica, the FDA appears a little reluctant to take some of the data for the drugmakers' antibiotic ceftobiprole at face value.
Pharmaceutical Executive October 1, 2008 Michael Bonney	Specialty Sales Gets No Resistance The author, a Cubist Pharmaceuticals CEO. has given his company a successful start and is now predicting the future of drug resistance.
The Motley Fool May 31, 2011 Brian Orelli	Down! Up! Which Way Will Optimer Go Next? Long-term prospects look good.
Chemistry World December 11, 2014	Merck to buy antibiotics specialist Cubist Hours after the deal was announced, a US District Court invalidated several key patents for Cubist's top seller, Cubicin (daptomycin).
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool February 1, 2008 Brian Lawler	AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs.
The Motley Fool August 31, 2010 Brian Orelli	A Mostly Meaningless FDA Rejection The Food and Drug Administration sends AstraZeneca back to the drawing board for the second time when it rejected motavizumab, the drugmaker's newest treatment for respiratory syncytial virus.
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool February 23, 2010 Brian Orelli	The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston.
The Motley Fool May 25, 2011 David Williamson	Pay Attention to Shire The British ADHD medicine maker is busy making big moves.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool May 25, 2011 Brian Orelli	Optimer's Upcoming FDA Decision: Memorable or Memorial? We'll know on Memorial Day, plus or minus a few days.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool December 12, 2007 Brian Lawler	Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation.
The Motley Fool May 29, 2009 Brian Orelli	The Clouds Are Parting The Food and Drug Administration has scheduled an advisory committee meeting for Aug. 4 to get input on whether the agency should approve generic versions of ViroPharma's antibiotic, Vancocin.
The Motley Fool December 21, 2010 Brian Orelli	4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday.
BusinessWeek December 29, 2010 Kelley & Cortez	AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs.
The Motley Fool July 11, 2011	Cubist Pharmaceuticals Earnings Preview Cubist Pharmaceuticals will unveil its latest earnings on Thursday.
The Motley Fool January 13, 2004 David Nierengarten	Vicuron's Booster Shot With a new "super-tough" antibiotic, Vicuron's stock is super high.
BusinessWeek June 2, 2011 Kresge & Connolly	A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies.
The Motley Fool September 30, 2008 Brian Lawler	Moody's Gets Moody With Drugmakers European pharmaceuticals get a negative rating from Moody's.
The Motley Fool January 9, 2009 Brian Orelli	Alnylam Holds Hands With a New Fella Is big pharma turning up its nose at RNAi drugs?
Chemistry World July 15, 2010 Matt Wilkinson	Biotechs plot path of least resistance Biopharmaceutical companies are moving into antibiotics, and filling the void left by big pharma.
The Motley Fool June 30, 2009 Brian Orelli	One-Drug Wonders Deserve a Spot in Your Portfolio Looking a little more appetizing these days.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool August 8, 2007 Brian Lawler	Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline.
Chemistry World April 27, 2011 Carol Stanier	Drug cocktails greater than the sum of their parts Canadian scientists have shown that combining an antibiotic that is past its prime with other drugs can give it a new lease of life.
The Motley Fool July 30, 2010 Cliff D'Arcy	Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline.
The Motley Fool July 30, 2007 Brian Lawler	AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy.